NCT05924672View on ClinicalTrials.gov

Efficacy of Ra-223 in PSMA PET Optimally Selected Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

August 30, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2028

Conditions
Castration-Resistant Prostate CarcinomaMetastatic Malignant Neoplasm in the BoneStage IVB Prostate Cancer AJCC v8
Interventions
DRUG

Radium-223

Given IV

PROCEDURE

PSMA Positron Emission Tomography (PET) Scan

Undergo PSMA PET/CT

DRUG

Technetium Tc 99M Medronate

Undergo MDP

Trial Locations (1)

94143

RECRUITING

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma

INDUSTRY

lead

University of California, San Francisco

OTHER